Thanks for helping to maintain perspective, OncoDoc...
It sounds reasonable to assume, given the potential timelines that you have addressed, that we could actually have interim data from the P2 cohorts & possibly even 12/24 week data from the 306 trial before the MTC indication even gets consideration for FDA review...regardless of EXAM trial data positivity.
Hopefully, the 306 trial SPA dialogue with FDA has gone well enough to provide a stock buffer should MTC data prove less than spectacular. Still, the prospect of picking up more shares in the $4's is not unattractive to me. Interesting times indeed... GLTA
the biggest risk you have to worry about is if it goes to zero. anything above that means it's still alive and kicking. if we could predict what it will do i think we would all be buying lotto tickets or heading to vegas.